Engineering New Druggable Surface
On August 26, 2026, the FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma—a landmark development for targeting the RAS signaling pathway. On August 26, 2026, the FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma—a landmark development for targeting the RAS signaling pathway. Clinical results showed an unprecedented ~2× improvement in overall […]